ATE316963T1 - Herstellung von sulfonamiden - Google Patents

Herstellung von sulfonamiden

Info

Publication number
ATE316963T1
ATE316963T1 AT00903628T AT00903628T ATE316963T1 AT E316963 T1 ATE316963 T1 AT E316963T1 AT 00903628 T AT00903628 T AT 00903628T AT 00903628 T AT00903628 T AT 00903628T AT E316963 T1 ATE316963 T1 AT E316963T1
Authority
AT
Austria
Prior art keywords
lower alkyl
hydrogen
hydroxy
alkoxy
alkyl
Prior art date
Application number
AT00903628T
Other languages
English (en)
Inventor
Bradley S Dehoff
Peter J Harrington
Hiralal N Khatri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE316963T1 publication Critical patent/ATE316963T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00903628T 2000-01-25 2000-01-25 Herstellung von sulfonamiden ATE316963T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00903628A EP1254121B1 (de) 2000-01-25 2000-01-25 Herstellung von sulfonamiden
PCT/EP2000/000556 WO2001055120A1 (en) 2000-01-25 2000-01-25 Preparation of sulfonamides

Publications (1)

Publication Number Publication Date
ATE316963T1 true ATE316963T1 (de) 2006-02-15

Family

ID=8163805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903628T ATE316963T1 (de) 2000-01-25 2000-01-25 Herstellung von sulfonamiden

Country Status (13)

Country Link
EP (1) EP1254121B1 (de)
JP (1) JP3751882B2 (de)
KR (1) KR100495550B1 (de)
CN (1) CN1178921C (de)
AT (1) ATE316963T1 (de)
AU (1) AU2000225442A1 (de)
CA (1) CA2397258C (de)
DE (1) DE60025803T2 (de)
DK (1) DK1254121T3 (de)
ES (1) ES2255973T3 (de)
MX (1) MXPA02007192A (de)
PT (1) PT1254121E (de)
WO (1) WO2001055120A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2686457A1 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Novel polymorphic forms
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
NZ585438A (en) * 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
EP2248805A3 (de) * 2008-01-01 2011-02-23 Cipla Ltd. Verfahren zur Herstellung von Bosentan, dessen polymorphe Formen und Salze
EP2240469A2 (de) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantiell reine und stabile kristalline form von bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CN101279948B (zh) * 2008-03-14 2010-08-11 苏州博鸿化工技术有限公司 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
CA2741928A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
RU2011145813A (ru) * 2009-04-13 2013-05-20 Сандох Аг Способ получения антагониста эндотелиального рецептора (бозентана)
EP2368884A1 (de) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Verfahren zur Herstellung von Bosentan
JP6129739B2 (ja) 2010-10-01 2017-05-17 ザック システム エス．ピー．エー．ＺａＣｈ Ｓｙｓｔｅｍ Ｓ．ｐ．Ａ． ボセンタン一水和物及びその中間体の製造方法
JP2015503555A (ja) * 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR102004422B1 (ko) * 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
AR095727A1 (es) * 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
CN114907275A (zh) * 2022-04-29 2022-08-16 武汉工程大学 一种波生坦的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (de) * 1992-12-10 1996-10-01 Hoffmann La Roche
HUT77534A (hu) * 1994-12-28 1998-05-28 Kowa Co. Ltd. Pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
KR100453097B1 (ko) * 1995-09-06 2004-12-31 코와 가부시키가이샤 피리미딘유도체

Also Published As

Publication number Publication date
DK1254121T3 (da) 2006-06-12
EP1254121B1 (de) 2006-02-01
ES2255973T3 (es) 2006-07-16
DE60025803T2 (de) 2006-11-02
CA2397258C (en) 2007-07-03
EP1254121A1 (de) 2002-11-06
WO2001055120A1 (en) 2001-08-02
KR100495550B1 (ko) 2005-06-16
JP3751882B2 (ja) 2006-03-01
AU2000225442A1 (en) 2001-08-07
PT1254121E (pt) 2006-06-30
CN1425007A (zh) 2003-06-18
JP2003520857A (ja) 2003-07-08
CA2397258A1 (en) 2001-08-02
KR20020070511A (ko) 2002-09-09
DE60025803D1 (de) 2006-04-13
MXPA02007192A (es) 2002-12-09
CN1178921C (zh) 2004-12-08

Similar Documents

Publication Publication Date Title
ATE316963T1 (de) Herstellung von sulfonamiden
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
ES8800720A1 (es) Un procedimiento para la preparacion de derivados carbonilicos de peptidasas electrofilicamente activadas.
AR241528A1 (es) Un procedimiento para la preparacion de n-(3- o 4-((alquilamino)alquil)-fenil)alcansulfonamidas y sus sales.
AU6679386A (en) 5-acylamido-1-aryl-pyrazoles
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
CA2081970A1 (en) Hiv protease inhibitors useful for the treatment of aids
ES2065133T3 (es) Derivados de piperazina.
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
CY1107710T1 (el) Εκκριματαγωγa αυξητικhς ορμoνης
EP0244115A3 (de) Phenylpiperazinderivate enthaltende anti-arrythmische Mittel
DK0699191T3 (da) Sulfonamider og derivater deraf, der modulerer aktiviteten af endotelin
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
ES2134764T3 (es) Inhibidores de hiv proteasa.
FI935517A0 (fi) Fenoxi- och fenoxialkylpiperidiner som virusmotverkande medel
FI832092L (fi) 1-aryloxi-2,3,4,5-tetrahydro-3-bensazepiner, foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel
FI941119A0 (fi) Menetelmä natriumkloridin teollisen vesilioksen valmistamiseksi ja näin saadun natriumkloridin vesiliuoksen käyttö natriumhydroksidin vesiliuoksen valmistamiseksi elektrolyyttisesti, natriumkarbonaatin valmistamiseksi ja natriumkloridikiteiden valmistamiseksi
DK0533790T3 (da) Hidtil ukendt saltform af 5-difluormethoxy-2-((3,4-dimethoxy-2-pyridyl)methylsulfinyl)-1H-benzimidazol
TR200101234T2 (tr) Endotelin antagonistleri.
ES8507112A1 (es) Un procedimiento para la prpeparacion de compuestos de 1,4-dihidropiridina.
IT1315267B1 (it) Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
ES8604922A1 (es) Procedimiento para la preparacion de n-piridilindoles
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
EA200400117A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов, обладающие антивирусной активностью, способ их получения (варианты) и способ лечения вирусной инфекции
DK0424802T3 (da) Tricykliske quinolinforbindelser med antineoplastisk aktivitet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254121

Country of ref document: EP